CA
ABBV icon

Capitolis Advisors’s AbbVie ABBV Stock Holding History

Capitolis Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-185,318
Closed -$25.1M – 148
2021
Q4 		$25.1M Buy
185,318
+22,345
+14% +$2.64M 0.15% 126
2021
Q3 		$17.5M Hold
162,973
– – 0.16% 113
2021
Q2 		$18.4M Sell
162,973
-179,738
-52% -$20.2M 0.22% 111
2021
Q1 		$37.1M Buy
342,711
+95,914
+39% +$10.3M 0.64% 34
2020
Q4 		$26.4M Buy
+246,797
New +$23.7M 0.44% 50

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capitolis Advisors's ABBV Position: Q1 2022 in Review

Capitolis Advisors sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 185,318 shares — an estimated $25.1M sold.

Capitolis Advisors first reported a position in ABBV in Q4 2020 and held it in 5 quarters. The position peaked at $37.1M in Q1 2021. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • Capitolis Advisors reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 185,318 AbbVie shares in Q1 2022, an estimated $25.1M.
  • Capitolis Advisors first reported a position in AbbVie in Q4 2020 and held it in 5 quarters.
  • Capitolis Advisors's AbbVie position peaked at $37.1M in Q1 2021.
  • 3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.